Isotechnika retains global rights to voclosporin



    EDMONTON, July 21 /CNW/ - (ISA:TSX): Isotechnika today announced that
Roche has given up its rights to license voclosporin for solid organ
transplant. This allows Isotechnika to open up the opportunity to license
voclosporin to potential partners for both transplant and autoimmune
indications. "Adding transplant to the list of available indications will
greatly strengthen our position and improve the attractiveness of the
opportunity to potential partners," states Dr. Robert Foster, Isotechnika's
Chairman and CEO.
    "While we are disappointed about Roche's different priorities, we feel
that this represents the first time since 2002 that we can offer a more
comprehensive licensing package including both transplant and autoimmune
indications to a focused and strong global partner," states Dr. Foster.
    "Our recently announced positive Phase 2b PROMISE trial results confirm
voclosporin as an effective immunosuppressive transplant treatment with an
improved safety profile," Dr. Foster added. "Voclosporin addresses a
significant medical need in the area of solid organ transplant and has the
potential to become an important and beneficial part of the immunosuppressive
regimens of transplant patients in the future."
    Isotechnika will now open up the licensing process to companies with a
strategic focus in this therapeutic area. Voclosporin is a unique opportunity
for partners focused on growing in a very significant market and looking to
strengthen their pipeline by adding a late stage product with excellent
commercial potential.
    The licensing process will be completed based on an accelerated schedule
that takes Isotechnika's interests and current market conditions into account.

    About Isotechnika
    -----------------
    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential will exceed $4 billion annually in sales
for calcineurin inhibitors such as voclosporin by 2010.
    Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LUVENIQTM by Lux) for the treatment of uveitis. Voclosporin
has also entered First-in-Man trials as the drug utilized in the CINATRA(TM)
Drug Coated Coronary Stent system developed by the Company's partner, Atrium
Medical Corporation.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at www.isotechnika.com or www.SEDAR.com.

    Forward-Looking Statements
    --------------------------
    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

    %SEDAR: 00010508E




For further information:

For further information: Robert Foster, Chairman & CEO, Isotechnika
Inc., Phone: (780) 487-1600 (x247), Fax: (780) 484-4105,
E-mail:rfoster@isotechnika.com; Stephanie Gillis-Paulgaard, Director,
Communications, Isotechnika Inc., Phone: (780) 909-4661, Fax: (780) 484-4105,
E-mail:sgillis-paulgaard@isotechnika.com

Organization Profile

ISOTECHNIKA PHARMA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890